Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 360 of the 360 references it cites were found in a registry or an index.

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Abstract

This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002. It is intended as a guide for the use of antimicrobial agents in managing patients with cancer who experience chemotherapy-induced fever and neutropenia. Recent advances in antimicrobial drug development and technology, clinical trial results, and extensive clinical experience have informed the approaches and recommendations herein. Because the previous iteration of this guideline in 2002, we have a developed a clearer definition of which populations of patients with cancer may benefit most from antibiotic, antifungal, and antiviral prophylaxis. Furthermore, categorizing neutropenic patients as being at high risk or low risk for infection according to presenting signs and symptoms, underlying cancer, type of therapy, and medical comorbidities has become essential to the treatment algorithm. Risk stratification is a recommended starting point for managing patients with fever and neutropenia. In addition, earlier detection of invasive fungal infections has led to debate regarding optimal use of empirical or preemptive antifungal therapy, although algorithms are still evolving. What has not changed is the indication for immediate empirical antibiotic therapy. It remains true that all patients who present with fever and neutropenia should be treated swiftly and broadly with antibiotics to treat both gram-positive and gram-negative pathogens. Finally, we note that all Panel members are from institutions in the United States or Canada; thus, these guidelines were developed in the context of North American practices. Some recommendations may not be as applicable outside of North America, in areas where differences in available antibiotics, in the predominant pathogens, and/or in health care–associated economic conditions exist. Regardless of venue, clinical vigilance and immediate treatment are the universal keys to managing neutropenic patients with fever and/or infection.

Overview

Integrity signals

Registry

Crossref · 10.1093/cid/cir073

Cites

360 of 360 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 360 references

Research works printed but not linked: 7

  1. Owens, 2000, Reduction in vancomycin consumption in patients with fever and neutropenia, Clin Infect Dis, 31, 291
  2. Rotstein, 1997, Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis, Opin Oncol, 4, 2
  3. Pasqualotto, 2006, Antibacterial prophylaxis in patients with cancer and neutropenia, N Engl J Med, 354, 90, 10.1056/NEJMc052613 · DOI
  4. Ito, 2006, Antibacterial prophylaxis in patients with cancer and neutropenia, N Engl J Med, 354, 90, 10.1056/NEJMc052613 · DOI
  5. Greene, 2007, Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign, Clin Infect Dis, 44, 373, 10.1086/509917 · DOI · Paper page
  6. Marks, 2009, Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients [abstract M-1249a]
  7. National Cancer Center Network (NCCN), 2009, Myeloid growth factors: NCCN practice guidelines

Cited by

See all 3,463

Metadata

Authors
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R.
Affiliations
  • University of Nebraska Medical Center (US)
  • CancerCare Manitoba (CA)
  • Memorial Sloan Kettering Cancer Center (US)
  • Fred Hutch Cancer Center (US)
  • City Of Hope National Medical Center (US)
  • University of Rochester Medicine (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Minnesota (US)
  • University of Florida (US)
Venue
Clinical Infectious Diseases
Published
2011-02-15
Volume
52
Issue
4
Pages
e56-e93
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2123859227
Cited by
3,463
References
360
Citations by year
2026: 176 · 2025: 180 · 2024: 163 · 2023: 211 · 2022: 233 · 2021: 245 · 2020: 260 · 2019: 277 · 2018: 254 · 2017: 267 · 2016: 218 · 2015: 247 · 2014: 248 · 2013: 221 · 2012: 174
FWCI
112.27
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
Keywords
febrile neutropenia, cancer, chemotherapy-induced neutropenia, antibiotic prophylaxis, antifungal prophylaxis, antiviral prophylaxis, risk stratification, invasive fungal infections, preemptive antifungal therapy, empirical antibiotic therapy, infection management
MeSH terms
Anti-Infective Agents, Antineoplastic Agents, Canada, Communicable Diseases, Fever of Unknown Origin, Humans, Neoplasms, Neutropenia, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. https://app.cochat.ai/papers/10.1093/cid/cir073
The paper
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011). Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cir073

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.